DK1664050T3 - Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem - Google Patents

Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem Download PDF

Info

Publication number
DK1664050T3
DK1664050T3 DK04782733.2T DK04782733T DK1664050T3 DK 1664050 T3 DK1664050 T3 DK 1664050T3 DK 04782733 T DK04782733 T DK 04782733T DK 1664050 T3 DK1664050 T3 DK 1664050T3
Authority
DK
Denmark
Prior art keywords
substituted
aryl
heteroalkyl
alkyl
alkenyl
Prior art date
Application number
DK04782733.2T
Other languages
English (en)
Inventor
Margaret Anne Brimble
Jian Guan
Frank Sieg
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK1664050T3 publication Critical patent/DK1664050T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (8)

1. Forbindelse med formlen:
eller et farmaceutisk acceptabelt salt eller hydrat deraf, hvor X1 er valgt fra gruppen bestående af NR', O og S; X2 er valgt fra gruppen bestående af CH2, NR', O og S; R1 er valgt fra gruppen bestående af -OR', -SR', -NR'R', -NO2, -CN, -C(0)R', -C(0)0R', -C(0)NR'R', -C(NR')NR'R', trihalogenmethyl, halogen, alkyl, substitueret alkyl, heteroalkyl, substitueret heteroalkyl, alkenyl, substitueret alkenyl, al-kynyl, substitueret alkynyl, aryl, substitueret aryl, heteroaryl, substitueret hetero-aryl, arylalkyl, substitueret arylalkyl, heteroarylalkyl og substitueret heteroarylal-kyl; hvert R' er uafhængigt valgt fra gruppen bestående af -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl og heteroarylalkyl; R2, R3, R4 og R5 er uafhængigt valgt fra gruppen bestående af -H, -OR', -SR', -NR’R’, -NO2, -CN, -C(0)R\ -C(0)0R\ -C(0)NR'R', -C(NR')NR Ή’, trihalogenmethyl, halogen, alkyl, substitueret alkyl, heteroalkyl, substitueret heteroalkyl, alkenyl, substitueret alkenyl, alkynyl, substitueret alkynyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, arylalkyl, substitueret arylalkyl, heteroarylalkyl og substitueret heteroarylalkyl; hvert R1 er uafhængigt valgt fra gruppen bestående af -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl og heteroarylalkyl; eller R4 og R5 taget sammen er -CH2-(CH2)n-CH2-, hvor n er et heltal fra 0 til 6; eller R2 og R3 taget sammen er -CH2-(CH2)n-CH2-, hvor n er et heltal fra 0 til 6; med det forbehold, at når R1=methyl, og R2=R3=R4=H, så er R5 φ benzyl; hvor en substitueret alkyl-, substitueret heteroalkyl-, substitueret alkenyl-, substitueret alkynyl-, substitueret aryl-, substitueret heteroaryl- eller substitueret arylal-kylgruppe er en alkyl-, heteroalkyl-, alkenyl-, alkynyl-, aryl-, heteroaryl- eller aryl-alkylgruppe, hvor et eller flere af hydrogenatomerne er uafhængigt erstattet med en anden substituent, som indbefatter -R', -OR', -SR', -NR'R', -NO2, -CN, -C(O)-R', -C(0)0R', -C(0)NR'R', -C(NR’)NR'R', -NR'-C(NR')-OR', -NR'-C(NR')-SR', NR'-C(NR')-NR'R', trihalogenmethyl og halogen, hvor hvert R' uafhængigt er -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl eller heteroarylalkyl.
2. Forbindelse ifølge krav 1, hvor R1=methyl eller allyl.
3. Forbindelse ifølge krav 1, hvor R2=R3=methyl, og X2=S.
4. Forbindelse ifølge krav 1, hvor R1=allyl, R2=R3=R4=R5=H, X1=NH, og X2=-CFI2 (cyklisk G-2AllylP); eller hvor R1=methyl, R2=R3=H, R4 og R5 taget sammen er -CH2-(CH2)3-CH2-, X1=NH, og X2=CFl2 (cyklisk cyclohexyl-G2MeP); eller hvor R1=methyl, R2=R3=H, R4 og R5 taget sammen er -CH2-(CH2)2-CH2-, X1=NH, og X2=CFl2 (cyklisk cyclopentyl-G2MeP).
5. Farmaceutisk sammensætning, som omfatter en forbindelse ifølge et hvilket som helst af de foregående krav og en farmaceutisk acceptabel excipiens.
6. En eller flere forbindelser ifølge et hvilket som helst af kravene 1 -4 til anvendelse til beskyttelse af neuroner, som ellers vil degenerere eller dø som følge af en skade eller en sygdom.
7. En eller flere forbindelser til anvendelse ifølge krav 6, hvor sygdommen er kendetegnet ved apoptotisk neurondød, nekrotisk neuroncelledød, neuroncelle-degenerering, eller hvor skaden resulterer i nekrotisk neuroncelledød, apoptotisk neuroncelledød eller neuroncelledegenerering.
8. En eller flere forbindelser til anvendelse ifølge krav 6, hvor forbindelsen er valgt blandt cyklisk G-2AllylP, cyklisk cyclohexyl-G-2MeP og cyklisk cyclopentyl-G-2MeP.
DK04782733.2T 2003-09-03 2004-08-31 Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem DK1664050T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
DK1664050T3 true DK1664050T3 (da) 2016-03-07

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04782733.2T DK1664050T3 (da) 2003-09-03 2004-08-31 Neurobeskyttende bicykliske forbindelser og farmaceutiske sammensætninger, der indeholder dem

Country Status (9)

Country Link
US (2) US8067425B2 (da)
EP (1) EP1664050B1 (da)
JP (1) JP4842817B2 (da)
DK (1) DK1664050T3 (da)
ES (1) ES2564803T3 (da)
HU (1) HUE028528T2 (da)
PL (1) PL1664050T3 (da)
SI (1) SI1664050T1 (da)
WO (1) WO2005023815A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8791117B2 (en) 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014066435A1 (en) * 2012-10-22 2014-05-01 City Of Hope Etp derivatives
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
SI3024463T1 (sl) 2013-07-25 2020-08-31 Neuren Pharmaceuticals Limited Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
SG10201912843YA (en) 2016-05-26 2020-02-27 Amino Up Chemical Co Ltd Sleep improving agent
CN109952104B (zh) 2016-09-15 2023-03-28 希望之城 二硫etp衍生物
CN119112885A (zh) 2018-03-16 2024-12-13 脑科学香料株式会社 缺氧障碍、缺血再灌注障碍或炎症的预防或治疗剂，移植用细胞保护剂，及生物体防腐剂
MA53500A (fr) 2018-05-15 2021-08-18 Lloyd Hung Loi Tran Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques
US12472177B2 (en) 2019-10-22 2025-11-18 Neuren Pharmaceuticals Limited Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome
IL305132A (en) * 2021-02-12 2023-10-01 Neuren Pharmaceuticals Ltd Preparations for the treatment of the Prader-Willi phenomenon
GEAP202416522A (en) * 2021-10-22 2024-08-26 Neuren Pharmaceuticals Ltd Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof
JP2024545685A (ja) * 2021-12-17 2024-12-10 ザ シージーピー ラボ リミテッド Ｃｇｐの動物、真菌及び海洋供給源、並びに疾患管理のための、並びに非神経学的及び／又は神経学的状態の治療のための増大したｃｇｐ濃度
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
FI941826L (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
AU2002340465A1 (en) * 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
CA2466701C (en) 2001-11-13 2013-11-12 Loi Tran Neuroprotective use of cyclic prolyl glycine
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use

Also Published As

Publication number Publication date
US8067425B2 (en) 2011-11-29
SI1664050T1 (sl) 2016-04-29
US20060258663A1 (en) 2006-11-16
WO2005023815A3 (en) 2005-07-21
JP4842817B2 (ja) 2011-12-21
ES2564803T3 (es) 2016-03-29
EP1664050B1 (en) 2015-12-09
PL1664050T3 (pl) 2016-08-31
EP1664050A2 (en) 2006-06-07
US7776876B2 (en) 2010-08-17
WO2005023815A2 (en) 2005-03-17
US20070197511A1 (en) 2007-08-23
JP2007504235A (ja) 2007-03-01
HUE028528T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
US8067425B2 (en) Neuroprotective bicyclic compounds and methods for their use
CA2790070C (en) Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
US8013170B2 (en) Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage
CN102159578B (zh) 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
AU2867899A (en) Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
US9119851B2 (en) Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
US7863304B2 (en) Analogs of glycyl-prolyl-glutamate
US8519127B2 (en) Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
EP1888618A2 (en) Analogs of glycyl-prolyl-glutamate
EP2403839A2 (en) Neurotrophin mimetics and uses thereof
US20250367192A1 (en) Bicyclic compounds and methods for their use in treating pitt hopkins syndrome
WO2008063311A2 (en) Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US6747042B2 (en) N-heterocyclic derivatives